Gutiérrez-Fernández María, Rodríguez-Frutos Berta, Ramos-Cejudo Jaime, Teresa Vallejo-Cremades M, Fuentes Blanca, Cerdán Sebastián, Díez-Tejedor Exuperio
Stem Cell Res Ther. 2013 Jan 28;4(1):11. doi: 10.1186/scrt159.
Stem cell therapy can promote good recovery from stroke. Several studies have demonstrated that mesenchymal stem cells (MSC) are safe and effective. However, more information regarding appropriate cell type is needed from animal model. This study was targeted at analyzing the effects in ischemic stroke of acute intravenous (i.v.) administration of allogenic bone marrow- (BM-MSC) and adipose-derived-stem cells (AD-MSC) on functional evaluation results and brain repair markers.
Allogenic MSC (2 × 106 cells) were administered intravenously 30 minutes after permanent middle cerebral artery occlusion (pMCAO) to rats. Infarct volume and cell migration and implantation were analyzed by magnetic resonance imaging (MRI) and immunohistochemistry. Function was evaluated by the Rogers and rotarod tests, and cell proliferation and cell-death were also determined. Brain repair markers were analyzed by confocal microscopy and confirmed by western blot.
Compared to infarct group, function had significantly improved at 24 h and continued at 14 d after i.v. administration of either BM-MSC or AD-MSC. No reduction in infarct volume or any migration/implantation of cells into the damaged brain were observed. Nevertheless, cell death was reduced and cellular proliferation significantly increased in both treatment groups with respect to the infarct group. At 14 d after MSC administration vascular endothelial growth factor (VEGF), synaptophysin (SYP), oligodendrocyte (Olig-2) and neurofilament (NF) levels were significantly increased while those of glial fiibrillary acid protein (GFAP) were decreased.
i.v. administration of allogenic MSC - whether BM-MSC or AD-MSC, in pMCAO infarct was associated with good functional recovery, and reductions in cell death as well as increases in cellular proliferation, neurogenesis, oligodendrogenesis, synaptogenesis and angiogenesis markers at 14 days post-infarct.
干细胞疗法可促进中风后的良好恢复。多项研究表明,间充质干细胞(MSC)安全有效。然而,需要从动物模型中获取更多关于合适细胞类型的信息。本研究旨在分析同种异体骨髓间充质干细胞(BM-MSC)和脂肪来源干细胞(AD-MSC)急性静脉注射对缺血性中风功能评估结果和脑修复标志物的影响。
在大鼠永久性大脑中动脉闭塞(pMCAO)30分钟后静脉注射同种异体MSC(2×10⁶个细胞)。通过磁共振成像(MRI)和免疫组织化学分析梗死体积、细胞迁移和植入情况。通过罗杰斯和转棒试验评估功能,并确定细胞增殖和细胞死亡情况。通过共聚焦显微镜分析脑修复标志物,并通过蛋白质免疫印迹法进行确认。
与梗死组相比,静脉注射BM-MSC或AD-MSC后24小时功能有显著改善,并在14天时持续改善。未观察到梗死体积减小或细胞向受损脑内的任何迁移/植入。然而,与梗死组相比,两个治疗组的细胞死亡均减少,细胞增殖显著增加。在MSC给药后14天,血管内皮生长因子(VEGF)、突触素(SYP)、少突胶质细胞(Olig-2)和神经丝(NF)水平显著升高,而胶质纤维酸性蛋白(GFAP)水平降低。
在pMCAO梗死模型中,静脉注射同种异体MSC(无论是BM-MSC还是AD-MSC)均与良好的功能恢复、细胞死亡减少以及梗死14天后细胞增殖、神经发生、少突胶质细胞生成、突触形成和血管生成标志物增加有关。